Literature DB >> 1734305

Myotonic dystrophy: clinical assessment of muscular disability in an isolated population with presumed homogeneous mutation.

J Mathieu1, M De Braekeleer, C Prévost, C Boily.   

Abstract

We evaluated the muscular disability of 295 patients affected by the adult form of myotonic dystrophy (DM) and living in the Saguenay-Lac-Saint-Jean region (Quebec, Canada). The patients are known to have a common ancestral couple, and a homogeneous DM mutation is presumed. Using a five-point muscular disability rating scale (MDRS), we confirmed, in each age group, the wide expressivity of the muscular involvement usually observed in DM. Based on the duration of the disease and the MDRS, we also found a great variation in the rate of disease progression. There were no significant relationships between the rate of disease progression and the sex of the patient, the sex of the affected parent, or the age at onset of the disease. Furthermore, there was an absence of association between the age at onset and the sex of the patient or the sex of the affected parent. The variable severity of the muscular involvement, and the absence of relationship between age at onset and rate of disease progression, suggest a multiallelic influence at the DM locus or at other loci.

Entities:  

Mesh:

Year:  1992        PMID: 1734305     DOI: 10.1212/wnl.42.1.203

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  19 in total

1.  Allele length of the DMPK CTG repeat is a predictor of progressive myotonic dystrophy type 1 phenotypes.

Authors:  Gayle Overend; Cécilia Légaré; Jean Mathieu; Luigi Bouchard; Cynthia Gagnon; Darren G Monckton
Journal:  Hum Mol Genet       Date:  2019-07-01       Impact factor: 6.150

2.  Towards an integrative approach to the management of myotonic dystrophy type 1.

Authors:  Cynthia Gagnon; Luc Noreau; Richard T Moxley; Luc Laberge; Stéphane Jean; Louis Richer; Michel Perron; Suzanne Veillette; Jean Mathieu
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-04-20       Impact factor: 10.154

3.  Fatigue and daytime sleepiness rating scales in myotonic dystrophy: a study of reliability.

Authors:  L Laberge; C Gagnon; S Jean; J Mathieu
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-10       Impact factor: 10.154

4.  Esophageal motor function in patients with myotonic dystrophy.

Authors:  M Costantini; G Zaninotto; M Anselmino; M Marcon; V Iurilli; C Boccù; G P Feltrin; C Angelini; E Ancona
Journal:  Dig Dis Sci       Date:  1996-10       Impact factor: 3.199

5.  Quantitative assessment of speech in myotonic dystrophy.

Authors:  B Maassen; J P ter Bruggen; A Nanninga-Korver; K van Spaendonck; L Weyn-Banningh; F Gabreëls
Journal:  J Neurol       Date:  1995-02       Impact factor: 4.849

6.  Ocular motor myotonic phenomenon in myotonic dystrophy.

Authors:  M Versino; B Rossi; G Beltrami; G Sandrini; V Cosi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-02       Impact factor: 10.154

7.  Psychopathological and emotional deficits in myotonic dystrophy.

Authors:  C Bungener; R Jouvent; C Delaporte
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-09       Impact factor: 10.154

8.  Myotonic dystrophy: correlation of clinical symptoms with the size of the CTG trinucleotide repeat.

Authors:  A Jaspert; R Fahsold; H Grehl; D Claus
Journal:  J Neurol       Date:  1995-01       Impact factor: 4.849

9.  Usefulness of clinical and electrocardiographic data for predicting adverse cardiac events in patients with myotonic dystrophy.

Authors:  Robert Breton; Jean Mathieu
Journal:  Can J Cardiol       Date:  2009-02       Impact factor: 5.223

10.  Is there a difference in gastric emptying between myotonic dystrophy type 1 patients with and without gastrointestinal symptoms?

Authors:  Yuji Tanaka; Tomohiro Kato; Hiroshi Nishida; Megumi Yamada; Akihiro Koumura; Takeo Sakurai; Yuichi Hayashi; Akio Kimura; Isao Hozumi; Hiroshi Araki; Masahiko Murase; Masahito Nagaki; Hisataka Moriwaki; Takashi Inuzuka
Journal:  J Neurol       Date:  2013-01-24       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.